Priya Bahri

855 citations

30 papers · 437 indexed · h-index 14

Impact in

Toxicology top 1%
- Pharmacovigilance and Adverse Drug Reactions
Geriatrics and Gerontology top 10%
- Pharmaceutical Practices and Patient Outcomes

Papers in

Toxicology 14
- Pharmacovigilance and Adverse Drug Reactions 14
Pharmacology 10
- Pharmaceutical industry and healthcare 10

Co-authors: Peter G. M. Mol Patrick Brown Xavier Kurz Jane Gidudu Ulrich Heininger Lembit Rägo Patricia McGettigan Kelly Plueschke
Journals: Drug Safety (14 papers)Pharmacoepidemiology and Drug Safety (4 papers)Vaccine (3 papers)Expert Opinion on Drug Safety (1 paper)Journal of the American Geriatrics Society (1 paper)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Priya Bahri

27 papers receiving 428 citations

Peers

Countries citing papers authored by Priya Bahri

Since Specialization

Citations

This map shows the geographic impact of Priya Bahri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Priya Bahri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Priya Bahri more than expected).

Fields of papers citing papers by Priya Bahri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Priya Bahri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Priya Bahri. The network helps show where Priya Bahri may publish in the future.

Co-authors

The 25 scholars most cited alongside Priya Bahri, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Priya Bahri Line = papers co-authored together Priya Bahri links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint Drug Safety ·Meredith Y. Smith, Rachel Davis, Priya Bahri, Delphine Saragoussi, Viviana Nguyen, Gita A. Toyserkani, Alison Brown	2025	0
2	Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations Pharmacoepidemiology and Drug Safety ·Thomas Goedecke, Liana Martirosyan, Nathalie Gault, Karin Seifert, Daniel R. Morales, Priya Bahri, Valerie Strassmann, Martin Huber, Sabine M. J. M. Straus	2024	1
3	The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System Drug Safety ·Priya Bahri, Georgy Genov, Peter Arlett, Viola Macolić Šarinić, Evdokia Korakianiti, Alexis Nolte, M. C. E. Huber, Sabine M. J. M. Straus	2024	2
4	The ISoP PatEG-SIG for Promoting Patient Engagement in Pharmacovigilance: A Change of Paradigm is Needed Drug Safety ·Manal M. Younus, Mayada Alkhakany, Priya Bahri, Angela Caro, Hadir Rostom, Helen Byomire Ndagije, Mohamed A. Elhawary	2023	4
5	How do safety warnings on medicines affect prescribing? Expert Opinion on Drug Safety ·Barbara Mintzes, Ellen Reynolds, Priya Bahri, Lucy T Perry, Alice L Bhasale, Richard L. Morrow, Colin R. Dormuth	2022	0
6	Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and Discourse Drug Safety ·Priya Bahri, Alexandre Pariente	2021	8
7	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States Clinical Pharmacology & Therapeutics ·Alice L Bhasale, Ameet Sarpatwari, Marie L. De Bruin, Joel Lexchin, Ruth Lopert, Priya Bahri, Barbara Mintzes	2020	15
8	Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET) Drug Safety ·Priya Bahri, Daniel R. Morales, Adrien Inoubli, Jean‐Michel Dogné, Sabine M. J. M. Straus	2020	10
9	‘Engagement’ of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological framework European Journal of Clinical Pharmacology ·Patrick Brown, Priya Bahri	2019	24
10	Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines Vaccine ·Miriam Sturkenboom, Priya Bahri, A Chiucchiuini, Tyra Grove Krause, Susan Hahné, Alena Khromava, M Kokki, Piotr Kramarz, Xavier Kurz, Heidi J. Larson, Simon de Lusignan, Patrick Mahy, Laurence Torcel‐Pagnon, Lina Titievsky, Vincent Bauchau	2019	17
11	Patient Registries: An Underused Resource for Medicines Evaluation Drug Safety ·Patricia McGettigan, Carla Olmo, Kelly Plueschke, Mireia Castillon, Daniel Nogueras Zondag, Priya Bahri, Xavier Kurz, Peter G. M. Mol	2019	52
12	CIOMS Guide To Vaccine Safety Communication – Executive summary Vaccine ·Priya Bahri, Lembit Rägo	2018	17
13	Application of real-time global media monitoring and ‘derived questions’ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines BMC Medicine ·Priya Bahri, Julianna Fogd, Daniel R. Morales, Xavier Kurz	2017	13
14	The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products Drug Safety ·Meredith Y. Smith, Andrea M. Russell, Priya Bahri, Peter G. M. Mol, Sarah Frise, Emily Freeman, Elaine H. Morrato	2017	19
15	The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance Drug Safety ·Priya Bahri, Alexander Dodoo, Brian Edwards, I. Ralph Edwards, Irene Fermont, Ulrich Hagemann, Kenneth Hartigan‐Go, Bruce Hugman, Peter G. M. Mol	2015	11
16	Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum Drug Safety ·Jürgen Beckmann, Ulrich Hagemann, Priya Bahri, Andrew Bate, Ian Boyd, Gerald J. Dal Pan, Brian Edwards, I. Ralph Edwards, Kenneth Hartigan‐Go, Marie Lindquist, John McEwen, Yola Moride, Sten Olsson, Shanthi Pal, Rachida Soulaymani Bencheikh, Marco Tuccori, Claudia Vaca, Ian Chi Kei Wong	2014	34
17	Communication in Drug Safety Drug Safety ·Priya Bahri, Peter G. M. Mol, Hélène Théophile, I. Ralph Edwards, Bruce Hugman	2011	4
18	Public Pharmacovigilance Communication Drug Safety ·Priya Bahri	2010	34
19	Pharmacovigilance‐related topics at the level of the International Conference on Harmonisation (ICH) Pharmacoepidemiology and Drug Safety ·Priya Bahri, Panos Tsintis	2004	19
20	Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects Journal of Clinical Epidemiology ·M. E. C. van Eijk, Priya Bahri, Gert Dekker, Ron M. C. Herings, A. J. Porsius, Jerry Avorn, Anthonius de Boer	2000	19

About Priya Bahri

Priya Bahri is a scholar working on Toxicology, Pharmacology, Health, Geriatrics and Gerontology and Economics and Econometrics, having authored 30 papers that have together received 437 indexed citations. Recurring topics across this work include Pharmacovigilance and Adverse Drug Reactions (14 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers), Pharmaceutical industry and healthcare (10 papers), Pharmaceutical studies and practices (7 papers), Vaccine Coverage and Hesitancy (5 papers), SARS-CoV-2 and COVID-19 Research (4 papers), Biosimilars and Bioanalytical Methods (4 papers) and Pharmaceutical Economics and Policy (4 papers). The work is most often cited by research in Toxicology (128 citations), Geriatrics and Gerontology (44 citations), Health (75 citations), Pharmacology (58 citations) and Economics and Econometrics (120 citations). Priya Bahri has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Peter G. M. Mol, Patrick Brown, Xavier Kurz, Jane Gidudu, Ulrich Heininger, Lembit Rägo, Patricia McGettigan, Kelly Plueschke, Carla Olmo and Meredith Y. Smith. Their work appears in journals such as Drug Safety, Pharmacoepidemiology and Drug Safety, Vaccine, Expert Opinion on Drug Safety and Journal of the American Geriatrics Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact